Browsing Tag
antibody-drug conjugate
14 posts
Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Antengene (SEHK: 6996.HK) presents ATG-125, ATG-106, and ATG-112 preclinical data at AACR 2026. Read what the results mean for its pipeline strategy.
Is DLL3 becoming the most strategic biomarker target in neuroendocrine oncology?
Can dual DLL3 targeting improve SCLC outcomes? Read PDN’s deep analysis of the Boehringer Ingelheim and Zai Lab collaboration today.
GlycoNex and Nippon Kayaku team up to advance next-generation ADC candidate GNX201-ADC in solid tumours
GlycoNex (4168) and Nippon Kayaku advance GNX201-ADC, a protease-activated ADC targeting solid tumours. Discover what this deal means for oncology. Read more.
Antengene deepens oncology ambitions with three next-generation ADC and T-cell engager programs at AACR 2026
Discover how Antengene Corporation Limited’s AACR 2026 oncology presentations could reshape its pipeline strategy and investor outlook. Read the full analysis.
Avacta (AIM: AVCT) opens AVA6103 Phase 1: Can sustained-release engineering salvage exatecan’s clinical legacy?
Avacta Therapeutics opens Phase 1 enrollment for AVA6103 exatecan PDC at two US oncology centers. Early data expected H2 2026. Read what it means for AVCT investors.
VERAXA Biotech clears final shareholder hurdle as Voyager Acquisition votes yes on $1.35bn oncology de-SPAC
Voyager Acquisition shareholders approve VERAXA Biotech combination. The cancer ADC and TCE platform heads to NASDAQ as VRXA. Read the full analysis.
Can immunotherapy finally replace chemo in bladder cancer? Keytruda–Padcev combo shows the way
Explore how Merck’s Keytruda and Padcev combo is redefining bladder cancer treatment without chemo. Survival gains, sector impact, and what’s next in focus.
Day One Biopharmaceuticals moves to acquire Mersana Therapeutics in $285m cancer-drug deal
Find out how Day One Biopharmaceuticals’ $285 million acquisition of Mersana Therapeutics could reshape the rare-cancer ADC landscape today.
FDA approves GSK’s Blenrep for myeloma—what sets it apart from CAR-T options?
GSK’s Blenrep approved by the FDA for relapsed multiple myeloma after Phase III trial success. Learn what this means for U.S. patients and global expansion.
Is this the most promising DLL3-targeting therapy yet? Zai Lab advances ADC into Phase 3
Zai Lab’s DLL3-targeting ADC for small cell lung cancer shows high brain metastasis activity; global Phase 3 trial now underway. Explore the data and future impact.